{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:15:28Z","timestamp":1785273328158,"version":"3.55.0"},"reference-count":21,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0759-x","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T15:27:31Z","timestamp":1573226851000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5618-0819","authenticated-orcid":false,"given":"Jocelyn","family":"Joseph","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Nathenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Anh","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Nowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiao-Pei","family":"Weathers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D.","family":"Demetri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejka","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony P.","family":"Conley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,11,8]]},"reference":[{"issue":"4","key":"759_CR1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/01.mph.0000161762.53175.e4","volume":"27","author":"CE Herzog","year":"2005","unstructured":"Herzog CE. Overview of sarcomas in the adolescent and young adult population. J Pediatr Hematol Oncol. 2005;27(4):215\u20138.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"759_CR2","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/ng0894-502","volume":"7","author":"J Clark","year":"1994","unstructured":"Clark J, Rocques PJ, Crew AJ, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet. 1994;7(4):502\u20138.","journal-title":"Nat Genet"},{"issue":"6","key":"759_CR3","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/hmg\/4.6.1097","volume":"4","author":"B Leeuw de","year":"1995","unstructured":"de Leeuw B, Balemans M, Olde Weghuis D. Geurts van Kessel a. identification of two alternative fusion genes, SYT-SSX1 and SYT-SSX2, in t(X;18)(p11.2;q11.2)-positive synovial sarcomas. Hum Mol Genet. 1995;4(6):1097\u20139.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"759_CR4","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/cncr.20386","volume":"101","author":"A Ferrari","year":"2004","unstructured":"Ferrari A, Gronchi A, Casanova M, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004;101(3):627\u201334.","journal-title":"Cancer"},{"issue":"2","key":"759_CR5","first-page":"1008","volume":"1","author":"SES Lange","year":"2014","unstructured":"Lange SES, Kremer JC, Schenone AD, et al. Current management and molecular targets of synovial sarcoma. Austin J Cancer Clin Res. 2014;1(2):1008.","journal-title":"Austin J Cancer Clin Res"},{"key":"759_CR6","doi-asserted-by":"publisher","first-page":"168145","DOI":"10.1155\/2013\/168145","volume":"2013","author":"RG Maki","year":"2013","unstructured":"Maki RG, Jungbluth AA, Gnjatic S, et al. A pilot study of anti-CTLA4 antibody ipilimumab I patients with synovial sarcoma. Sarcoma. 2013;2013:168145.","journal-title":"Sarcoma"},{"key":"759_CR7","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicenter, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18:1493\u2013501.","journal-title":"Lancet Oncol"},{"key":"759_CR8","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","volume":"19","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo SP, Mahoney MR. Van tine Ba, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomized, phase 2 trials. Lancet Oncol. 2018;19:416\u201326.","journal-title":"Lancet Oncol."},{"key":"759_CR9","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/modpathol.2012.31","volume":"25","author":"JP Lai","year":"2012","unstructured":"Lai JP, Robbins PF, Raffeld M, et al. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis. Modern Pathol. 2012;25:854\u20138.","journal-title":"Modern Pathol"},{"key":"759_CR10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/modpathol.2014.155","volume":"28","author":"M Endo","year":"2015","unstructured":"Endo M. deGraaff MA, Ingram DR, eta. NY-ESO-1 expression in mesenchymal tumors. Mod Pathol. 2015;28:587\u201395.","journal-title":"Mod Pathol"},{"issue":"13","key":"759_CR11","first-page":"3630","volume":"62","author":"G Zeng","year":"2002","unstructured":"Zeng G, Li Y, El-Gamil M, et al. Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res. 2002;62(13):3630\u20135.","journal-title":"Cancer Res"},{"issue":"5","key":"759_CR12","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","volume":"21","author":"P. F. Robbins","year":"2014","unstructured":"Robbins PF, Kassim SH, Tran TL, et al. A pilot trial using lymphocytes genetically engineered with n NY-ESO-1 reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21(5):1019\u201327.","journal-title":"Clinical Cancer Research"},{"issue":"8","key":"759_CR13","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","volume":"8","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo SP, Melchiori L, Merchant MS, et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1c-259T cells in synovial sarcoma. Cancer Discov. 2018;8(8):944\u201357.","journal-title":"Cancer Discov"},{"key":"759_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ensci.2016.08.001","volume":"4","author":"T Yoshida","year":"2016","unstructured":"Yoshida T, Ueki Y, Suzuki T, et al. Guillain-Barre syndrome after allogeneic bone marrow transplantation: case report and literature review. eNeurologicalSci. 2016;4:52\u20135.","journal-title":"eNeurologicalSci"},{"key":"759_CR15","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1212\/WNL.49.6.1711","volume":"49","author":"PY Wen","year":"1997","unstructured":"Wen PY, Alyae EP, Simon D, et al. Guillain-Barre syndrome following allogeneic bone marrow transplantation. Neurology. 1997;49:1711\u20134.","journal-title":"Neurology"},{"issue":"9","key":"759_CR16","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1086\/368311","volume":"36","author":"PJ Piliero","year":"2003","unstructured":"Piliero PJ, Fish DG, Preston S, et al. Guillain-Barre syndrome associated with immune reconstitution. Clin Infect Dis. 2003;36(9):e111\u20134.","journal-title":"Clin Infect Dis"},{"issue":"suppl 4","key":"759_CR17","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBAG Haanen","year":"2017","unstructured":"Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv119\u201342.","journal-title":"Ann Oncol"},{"issue":"9","key":"759_CR18","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1023\/A:1008362714023","volume":"11","author":"DA Anthoney","year":"2000","unstructured":"Anthoney DA, Bone I, Evans TR. Innflammatory demyelinating polyneuropathy: a complication of immunotherapy in malignant melanoma. Ann Oncol. 2000;11(9):1197\u2013200.","journal-title":"Ann Oncol"},{"issue":"1","key":"759_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/glia.20903","volume":"58","author":"G Meyer Zu Horste","year":"2010","unstructured":"Meyer Zu Horste G, Heidenreich H, Lehmann HC, et al. Expression of antigen processing and presenting molecules by Schwann cells in inflammatory neuropathies. Glia. 2010;58(1):80\u201392.","journal-title":"Glia"},{"issue":"3","key":"759_CR20","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1212\/WNL.47.3.668","volume":"47","author":"LH Visser","year":"1996","unstructured":"Visser LH, van der Mech\u00e9 FG, Meulstee J, et al. Cytomegalovirus infection and Guillain-Barr\u00e9 syndrome: the clinical, electrophysiologic, and prognostic features Dutch Guillain-Barr\u00e9 Study Group. Neurology. 1996;47(3):668\u201373.","journal-title":"Neurology"},{"issue":"2","key":"759_CR21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5114\/aoms.2010.13912","volume":"6","author":"A Tomaszewska","year":"2010","unstructured":"Tomaszewska A, Nasilowska-Adamska B, Dzieciatkowski T, et al. Simultaneous human herpesvirus 6-associated encephalitis and Guillain-Barr\u00e9 syndrome in a patient after matched unrelated donor haematopoietic stem cell transplantation. Arch Med Sci. 2010;6(2):288\u201390.","journal-title":"Arch Med Sci"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0759-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0759-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0759-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:45:39Z","timestamp":1601055939000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0759-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,8]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["759"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0759-x","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,8]]},"assertion":[{"value":"3 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The present study was conducted in accordance with all accepted standard for the ethical conduct of human subject\u2019s research. Written informed consent was obtained from the patient at the time of enrollment. Approval was obtained from GSK and Adaptimmune for publication of this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication has been obtained for both patient cases.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SPW reports research support from Genentech and Mundipharma. AC receives research support from Ignyta, Iovance, Nektar, and Novartis. All other authors report no disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"296"}}